Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
A1 Receptor
100%
Receptor Agonist
100%
Glucagon-like
100%
Exendin-4 (Ex-4)
100%
Ethanol
42%
Liver
28%
Hepatic Steatosis
28%
Fat Metabolism
28%
Feeding Practices
14%
Blood Samples
14%
Beneficial Effects
14%
Advanced Stage
14%
Alcohol
14%
Early Response
14%
Insulin
14%
Serum ALT
14%
Liver Disease
14%
Fatty Liver
14%
Triglyceride Level
14%
Insulin Resistance
14%
Wistar Rats
14%
Every Other Day
14%
Alcohol-induced
14%
Chronic Alcohol
14%
Hormone Levels
14%
Tissue Sampling
14%
Preclinical Animal Models
14%
Ethanol Intake
14%
Euthanized
14%
Liebe
14%
Body Weight Gain
14%
Alcohol Administration
14%
Body Weight Ratio
14%
Insulin Signaling
14%
Hepatic Fat
14%
Adiponectin
14%
Metabolic Hormones
14%
Hepatic Lipid Accumulation
14%
Glucose Tolerance Test
14%
Metabolic-associated Fatty Liver Disease (MAFLD)
14%
Biochemistry, Genetics and Molecular Biology
Body Weight
100%
Lipid Metabolism
100%
Receptor Agonists
100%
Glucagon-Like Peptide 1 Receptor
100%
Rat Model
50%
Triacylglycerol Level
50%
Glucose Test
50%
Glucose Tolerance Test
50%
Insulin Resistance
50%
Wistar Rat
50%
Lipid Storage
50%
Body Weight Gain
50%
Insulin Signaling
50%
Adiponectin
50%
Experimental Rat
50%
Glucagon-Like Peptide-1
50%
Pharmacology, Toxicology and Pharmaceutical Science
Fatty Liver
100%
Ethanol
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Exendin 4
100%
Fatty Acid
14%
Liver Disease
14%
Triacylglycerol
14%
Insulin Resistance
14%
Wistar Rat
14%
Rat Model
14%
Adiponectin
14%
Experimental Rat
14%
Glucagon-Like Peptide-1
14%